Source Cambridge Clinical Laboratories Strengthen Preventative Health Offering Through Expanded Hereditary Cancer Testing Services

Source Cambridge Clinical Laboratories (Source CCL), part of Source BioScience UK Ltd, is strengthening its preventative health and oncology diagnostics offering through its established hereditary cancer testing services, supporting earlier risk identification and more informed clinical decision-making across the patient pathway.

Hereditary cancer testing plays a critical role in modern healthcare, enabling the identification of inherited cancer risk and supporting both individual patient management and broader population health strategies. As demand for earlier intervention and preventative approaches continues to grow, access to reliable and flexible germline testing is becoming increasingly important.

As part of its specialist oncology testing laboratory, Source CCL is expanding hereditary cancer testing services across multiple sample collection methods, including blood and saliva-based testing. This dual-sample capability provides clinicians with greater flexibility when selecting the most appropriate and practical testing pathway, helping to remove barriers to access while maintaining high standards of quality and accuracy.

Importantly, hereditary cancer testing forms a key component of the wider oncology diagnostic pathway. Source CCL services are designed to complement its broader portfolio, which spans early cancer detection, diagnostic and prognostic testing, as well as treatment stratification and disease surveillance. Together, these capabilities enable a more integrated approach to cancer care, from risk assessment through to ongoing patient management.

By continuing to invest in and expand its hereditary cancer testing services, Source CCL reinforces its commitment to advancing precision medicine and improving patient outcomes through accessible, high-quality genomic diagnostics.

Executive Quote

Jay LeCoque, Executive Chairman and CEO, commented:

"Enabling greater patient access to hereditary cancer testing marks an important advancement in our commitment to more proactive, personalised oncology care. By expanding this service, we can better support earlier risk identification for both individual patients and population health, further strengthening our position as an end-to-end provider of oncology screening and diagnostic services”.

About Source Cambridge Clinical Laboratories

In April 2025, Source BioScience UK Ltd, a leading provider of genomic services and histopathology diagnostics, acquired Cambridge Clinical Laboratories (CCL), to complement established capabilities in genomics and multi-omics, and expands its existing clinical offering, which includes molecular diagnostics, digital pathology and clinical trial support, to provide a complete laboratory service portfolio. By offering comprehensive, end-to-end testing solutions, researchers can confidently progress candidates through R&D, to preclinical and clinical stages with one specialist outsourcing partner – minimising resource requirements and data bias across the entire development process, with the option for additional support in clinical research and diagnostics.

Website: www.sourcebioscience.com